Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ORPHAN DRUG AMENDMENT PROPOSAL REDUCES MARKET EXCLUSIVITY

Executive Summary

ORPHAN DRUG AMENDMENT PROPOSAL REDUCES MARKET EXCLUSIVITY to five years, but allows sponsors of products with "limited commercial potential" to apply for a five-year extension. The proposal was drafted by member companies of BIO, the merging Industrial Biotechnology Association and the Association of Biotechnology Companies, and circulated on Capitol Hill during the week of May 24. The industry proposal is prospective and is drafted to apply only to orphan products for which clinical trials have not yet begun. The draft provides that "no earlier than four years after approval" of an orphan drug, the sponsor could apply to FDA for a five-year extension of market exclusivity. To qualify for an extension, the product's patient population must be limited to 100,000 patients or fewer. The patient threshold for initial orphan designation is 200,000, as under current law. The proposal places the burden on the company to document that the product has "limited commercial potential," and competitors may submit evidence to the contrary. The draft notes that evidence might include the number of companies investigating the drug, the number of countries where a marketing application is pending and the prevalence of the indicated condition. Companies have been criticized for seeking orphan designations to obtain market exclusivity for biotechnology products that otherwise cannot qualify for patent protection. To address such situations, the industry draft proposes an alternative in which companies can obtain four-year market exclusivity for biotech products. The proposal defines a biotech product as a drug or biological product "primarily developed or manufactured using recombinant DNA technology, recombinant RNA technology, hybridoma technology, computer-aided amino acid sequence selection and identification or other processes involving site-specific genetic manipulation techniques, or...protein, peptide or biopolymer extracted from a cellular source." Under a proposed system that would parallel FDA's orphan drug procedures, the agency will not approve duplicates of a biotech drug or biological "for use in any disease or condition," regardless of the size of the patient population. FDA may approve competing versions under the proposal only if there are shortages of the first approved product during the four-year exclusivity period, the owner of the first product consents to marketing of the competing version, or the products were developed simultaneously. The draft defines products developed simultaneously as those for which marketing applications were submitted to FDA within 12 months of one another. The companies sent the proposal to Sens. Kennedy (D-Mass.), Metzenbaum (D-Ohio), Kassebaum (R-Kan.) and Hatch (R-Utah) and Reps. Waxman (D-Calif.) and Bliley (D-Va.). The industry reportedly is awaiting an indication of support from the legislators.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS022827

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel